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C1 protein production platform has been developed through more than 20 years of commercial genetically
engineering. The thermophilic fungus Thermothelomyces heterothallica is a robust and versatile fungal
expression system for the rapid production of proteins at very high levels. In the last 6 years, the C1 protein
production platform has been further improved to become a safe and efficient expression system with the prime
objective of speeding up the development and production of commercial scale human and animal vaccines,
monoclonal antibodies, biosimilars, as well as other therapeutic proteins at larger quantities and lower cost.
C1 is a very efficient platform to produce antigens, even to generate multicomponent vaccines. The production
levels of engineered C1 strains are similar in terms of yield and purity, reaching in some cases more than 2.5
g/L (in 4-5 days). In contrast to other vaccine platforms, C1 has a higher safety profile, and production can be
scaled up in a more cost-effective manner using standard microbial E. coli fermenters. Stable cell lines have
been developed to produce different antigens as influenza, neuraminidase, west Nile, rabies, rift valley
fever..etc.
Here we present the production of Dyadic´s DYAI-100 vaccine candidate against the Covid-19 pandemic, based
on the ~25 kilodalton-large Receptor Binding Domain (RBD) within the S1 subunit that was identified as the
most effective SARS-CoV-2 neutralizing antibodies described to date. The use of C1 as vaccine production
platform against the SARS-CoV-2 offers several advantages as follows:
(i) The C1 platform can support the global immunization strategies that are needed against emerging new
SARS-Covid-2 variants. In 7 weeks, new RBD variant’s genes can be inserted into the same C1 cell line (same
genotype) to develop stable cell lines which can be used to produce antigens at the same production levels (1-2
g/L) in 4-5 days. So far, the following variants were successfully produced; Alpha (UK), Beta (SA) Gamma (BR)
Delta (Ind) and Omicron (B.1.1.529) at levels and qualities that are similar to the Wuhan RBD – DYAI-100.
(ii) Safety and Persistence - the results show that DYAI-100 elicits safe, effective, and protective immune
responses in several successful mice studies including challenge study with hACE2-transgenic C57BL/6J mice
that demonstrated full protection without adverse events. Importantly, a rabbit toxicology study demonstrated
that the C1-SARS-CoV-2 RBD vaccine candidate is safe and has the potential to be an effective vaccine with a
safety and tolerability profile suitable for evaluation in humans. In addition, the study suggested a major
beneficial effect of the vaccination demonstrating continued, and not declining antigenic stimulation, for relatively
long duration, without any local or systemic adverse effect.
This DYAI-100 vaccine candidate has been produced under GMP standards (99% purity) and proposed for
further testing in safety and efficacy clinical trials.

Figure 1: C1 RBD strain was run in 5L scale fermentation. The RBD was purified through CaptureSelectTM
Ctag column rendering 98% purity, 70% recovery. Figure 2: (2a) The iliac lymph nodes from an animal injected
with the Alhydrogel®‘85’ (Placebo) and (2a) and with C1-RBD Vaccine (2b) after sacrificed 42 days post first
dosing (Recovery phase). Note, arrowheads in 2a- no evidence of germinal centers. The lesions (arrowhead in
2b) consist of mild germinal centers increased lymphocytic cellularity (i.e., follicular hyperplasia).
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